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Abstract  
Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with 
approximately 71 million chronically infected individuals worldwide. Treatment of chronic 
hepatitis C has considerably improved in the last few years thanks to the introduction of direct 
acting antivirals able to achieve sustained virological response in more than 95% of patients. 
Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-
hepatic manifestations, eventually reducing liver-related and overall mortality.  
Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access 
to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group 
of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this 
meeting and the final statements are reported in this paper. 
Expert commentary: All the advances on HCV cure may have a real clinical impact not only in 
individual patients but also at the social health level if they are applied to all infected patients, 
independently from the stage of liver disease. Further improvements are needed in order to 
attain HCV elimination, such as the development of an enhanced screening program working in 
parallel to the present treatment options. 
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Article highlights 
• Treatment of chronic hepatitis C has considerably improved in the last few years thanks to 
the introduction of DAAs able to achieve SVR in more than 95% of patients.  
• Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related 
extra-hepatic manifestations, eventually reducing liver-related and overall mortality.  
• All the advances on HCV cure may have a real clinical impact at the social health level if 
they are applied to all infected patients, independently from the stage of liver disease.  
• Treating patients with early liver disease today will in fact, in the future, reduce the 
mortality related to the progression of liver injury and extrahepatic complications, curb the 
transmission of infection and improve the patients' quality of life.  
• In order to attain HCV elimination we should develop and/or enhance screening program 
both in the general population and in the higher risk patients and linkage to care from all 
infected patients.  
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1 Introduction 
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide and 
is responsible for a large proportion of liver-related deaths, mostly due to  hepatocellular carcinoma 
(HCC) and cirrhosis complications (1,2). Approximately at least 71 million people worldwide are 
currently infected with HCV, although reliable epidemiological data are elusive in most Countries, 
including Italy (1). Antiviral treatment of chronic hepatitis C (CHC) has been revolutionized by the 
introduction of direct acting antivirals (DAAs) able to achieve sustained virological response (SVR) 
in more than 95% of patients. SVR has been associated with the reduction of HCV transmission, 
improvement of hepatic inflammation and fibrosis, liver function and survival (1). DAAs target key 
steps of HCV replication and can be divided into 4 classes based on their target and mechanism of 
action: NS3 protease inhibitors (PIs), NS5B polymerase inhibitors [nucleos(t)ide and non-
nucleoside inhibitors, NI and NNI, respectively] and NS5A inhibitors. Combination of different 
classes of DAAs is essential to achieve SVR. 
In Italy, the introduction of DAAs in the clinical practice followed two different phases of 
reimbursement. In the first, the Italian Medical Agency (AIFA) reimbursed Sofosbuvir (SOF), 
SOF/Ledipasvir (LDV), SOF/Daclatasvir (DCV), SOF/Simeprevir and 
Ombitasvir/Paritaprevir/Ritonavir±Dasabuvir only for patients with severe hepatic fibrosis or 
cirrhosis (defined according to liver histology, i.e. F≥3 according to METAVIR or S≥4 at the Ishak 
score, and by liver stiffness measurements by Fibroscan ≥10 kPa), with treated HCC, with liver 
transplant (LT) and with HCV-related extra-hepatic manifestations (EHMs). From March 2017, 
SOF/Velpatasvir (VEL), Grazoprevir (GZR)/Elbasvir (EBR) and from October 2017 
Glecaprevir/Pibrentasvir (GLE/PIB), are reimbursable for all the HCV infected patients, whereas 
the combination of SOF/VEL/Voxilaprevir (VOX) is reimbursable since April 2018 only for those 
who have failed a previous DAA-based regimen. 
Ac
ce
pte
d M
an
us
cri
pt
 
Among the 71.345 patients treated till March 2017, 45% had cirrhosis, 23% F3 fibrosis and 26% 
F1-F2 fibrosis. At the end of May 2018, 138.731 patients had been treated with DAAs with the aim 
to treat 350.000 subjects by 2020. However, the lack of reliable epidemiological data on HCV 
prevalence, in general population as well as in patient’s categories at higher risk of infection (men 
who have sex with men, prisoners, people who inject drugs), has not yet allowed to plan a strategy 
for screening and treatment.  
Currently, the approved DAAs in Italy fall into 2 subcategories: the SOF-based regimens including 
the combination of the NS5B polymerase NI (SOF) plus an NS5A inhibitor (VEL) and the 
combination of SOF, VEL and a PI (VOX); the non-SOF based regimens including the combination 
of PI (GZR) plus an NS5A inhibitor (EBR) or the combination of PI (GLE) plus an NS5A inhibitor 
(PIB). All SOF-based regimens and GLE/PIB show pangenotypic activity, while GZR/EBR is 
restricted to HCV-1 and 4. SOF/VEL/VOX and GLE/PIB are ribavirin (RBV)-free regimens and 
SOF/VEL needs RBV in decompensated cirrhotic patients and may be used with RBV in HCV-3 
cirrhotic patients. RBV is also required in HCV-1a and HCV-4 patients with HCV RNA >800.000 
IU/ml and/or the presence of specific NS5A polymorphisms treated with GZR/EBR (3,4). However, 
given that RBV is not devoid of side effects, when possible, RBV-free regimens should be the 
preferred treatment option (1).  
In patients with compensated cirrhosis [Child Pugh Turcotte (CPT) class A], all DAAs can be safely 
administered, whereas in patients with hepatic impairment (CPT B and C), use of DAAs is feasible 
but caution should be used (1). Current DAAs show two distinct pharmacological features in 
cirrhotic patients. The pharmacokinetics (PK) modification of NS5B polymerase inhibitor and 
NS5A inhibitors, even in CPT B and C patients, are minimal and compatible with expected safety 
and efficacy (5). On the other hand, plasma concentrations of PIs increase proportionally with the 
degree of liver impairment, leading to liver function deterioration, hepatic decompensation and 
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death. For that reason any DAA regimen that includes PIs needs to be avoided in CTP B and C 
patients and in those with a previous hepatic decompensation (1).  
Kidney function also guides the choice of DAA, indeed it is mandatory to identify patients with a 
stage 4/5 [estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2] of Chronic Kidney 
Diseases (CKD). Although real-life data have shown a relatively safe profile for SOF in subjects 
with eGFR <30 ml/min/1.73m2, this drug remains still not recommended in such patients, as an 
increase of up to 20 times of GS-331007, the dephosphorylation-derived SOF nucleoside 
metabolite, has been reported (1,6,7). GZR/ELB or GLE/PIB are the two combinations 
of DAAs approved for the treatment of HCV patients with a stage 4/5 CKD (8,9).  
Current DAAs show a limited potential for drug to drug interaction (DDI), that are not dependent 
on  metabolic interference, i.e. CYP3A4-mediated, but rather on inhibition of drug transporters, 
both at intestinal (PgP, BRCP) and hepatic level (OATP1B1, OATP1B3) (1). Although DDIs with 
some of the most used concomitant drugs have been formally evaluated (proton pump inhibitors, 
statins, calcium channel blockers, methadone, buprenorphine, immunosuppressant) the wide 
therapeutic ranges of DAAs protect them from DDIs and facilitates the management of the latter, 
but knowledge of PK and pharmacodynamics (PD) data are crucial. Moreover, the possible effects 
of DAAs on concomitant drugs should rely again on PK/PD data. Therefore, management of 
concomitant drugs with poor or no PK data, i.e. cardiovascular (anti-platelets, anticoagulants, anti-
arrhythmic), neuroactive (antipsychotics, neuroleptics, antidepressants) or cancer drugs, needs more 
clinical data to overcome the uncertainty of current recommendations.  
1.1 Statements 
• Due to Italian reimbursement rules these DAA regimens are the standard of care options for 
HCV-infected patients: 
- in DAA-naïve: SOF/VEL, GZR/EBR, GLE/PIB  
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- in DAA-experienced: SOF/VEL/VOX, (SOF+GLE/PIB and SOF+GZR/EBR pending 
reimbursement)  
• RBV-free regimens should be the first line treatment when available 
• Regimens which include PIs are contraindicated in CPT B and C patients and in those with 
a previous hepatic decompensation 
• CPT A patients are heterogeneous in terms of liver function and therefore PI-containing 
regimens should be used with caution in patients with borderline surrogate parameters (low 
albumin and platelets levels) of liver dysfunction 
• Regimens which include SOF should not be the first choice in patients with eGFR <30 
ml/min/1.73m2. However, in specific conditions when PIs are contraindicated SOF could be 
used with caution 
• Wide therapeutic ranges of DAAs protect from DDIs but knowledge of PK/PD clinical data 
are crucial for an appropriate evaluation of the risk  
• Although potential for DDIs is limited and manageable, in most cases there is a substantial 
lack of PK and PD data for several classes of drugs, making uncertain current 
recommendations 
2. Real life experience with DAAs in Italy 
In order to assess the overall effectiveness of DAAs in Italian real-life, we retrospectively collected 
the data of three Hepatitis C Registries (Lombardia, Sicilia and Pisa) including all CHC infected 
patients over 18 years with available SVR data 12 weeks after the end of DAA-based treatment. 
Stage of liver disease was assessed on clinical ground, by liver biopsy or liver stiffness 
measurements (LSM) by Fibroscan, considering as cirrhosis LSM ≥12 kPa. Overall, 10,711 patients 
were included; the majorities were middle age cirrhotic males, infected with genotype 1 (Table 1). 
Overall, 10,248 (96%) patients achieved SVR: 96% vs 95.5% vs 90.4% in patients without 
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cirrhosis, with compensated and decompensated cirrhosis, respectively. During the median 9 (0-36) 
months of follow-up after the end of treatment, 184 (1.8%) patients developed an HCC: 1.6% vs 
7.3% in patients with and without SVR, respectively; 68 (0.9%) patients decompensated: 0.9% vs 
2.8% in patients with and without SVR, respectively and 94 (0.9%) patients died: 0.7% vs 4.7% in 
those with and without SVR, respectively. Despite our collection lacks a long follow-up after the 
end of treatment it represents an interesting cohort due to the huge number of patients treated in a 
real practice confirming the effectiveness of DAAs regimens (10,11). 
3. The clinical benefits of treatment with DAAs  
SVR corresponds to the cure of HCV infection and is generally associated with normalization of 
liver enzymes and improvement or disappearance of liver inflammation and fibrosis in patients 
without cirrhosis. DAAs have shown high efficacy and safety also in patients with advanced liver 
disease, in which hepatic fibrosis may regress, and the risk of complications may be reduced after 
SVR (1,2). Moreover, the virologic response in patients with advanced liver disease has been found 
to be associated with an improvement of liver function evaluated by CTP and MELD scores, with a 
concomitant mortality reduction (10,11). Although first data have reported an high rate of HCC 
incidence and recurrence after DAAs (12,13), most recent data from large cohorts have suggested 
that HCC incidence in cirrhotic patients with an SVR decreases over time, and do not suggest an 
increased risk of recurrence, which is instead related to the timing of DAAs after the HCC cure (14-
19). The predictors of HCC in patients with SVR are: older age, low platelets count, low albumin 
values, advanced liver fibrosis and higher levels of serum alpha fetoprotein (AFP). On the other 
hand, cirrhotic patients who fail DAA treatment are a high risk group for HCC development. To 
date, all cirrhotic patients, regardless of the SVR achievement, should be maintained on surveillance 
for HCC with semiannual ultrasonography (US) (20).  
Moreover, an increasing number of evidences associate DAA treatment with the clinical reduction 
of the impact of extra-hepatic manifestations (EHMs). Concerning cryoglobulinemic vasculitis, 
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there is a general evidence that 90 to 100% of the subjects acquire an SVR after treatment, although 
the clinical response can be limited to about one third of the treated subjects (21,22). Concerning 
the metabolic modification induced by DAAs, there is a clear evidence that after SVR the glycemic 
control improves in patients with diabetes (23,24), HDL-cholesterol plasma levels increase (25) and 
carotid atherosclerosis improves (26). The long-term beneficial effect of HCV elimination on 
hepatic and extra-hepatic morbidity and mortality after treatment with DAA begins to be evident, 
and it will be even more in the near future. 
3.1 Statements 
- All patients with HCV infection and EHMs should be treated with DAAs because there is a 
clinical improvement with a reduction of disease progression, except those with limited life 
expectancy (<12 months) 
 
4. DAAs in decompensated cirrhosis 
Treatment of decompensated patients remains a challenge. In both clinical trials and real-life 
reports, SVR rates progressively decrease with worsening of liver function: from rates >95% in 
CTP A, to 80-90% in CTP B, and <75% in CTP C (27-30). However, this decrease in SVR rates 
reflects both non virological (death due to liver disease progression) and virological failure. Patients 
with decompensated cirrhosis non-responders to DAAs usually do not have baseline HCV-
resistance associated substitutions (RASs) or poorer adherence, compared to responders. A recent 
report has shown that non-response in such patients can be associated with a number of 
immunological dysfunctions (elevated basal CXCL-10 serum level compared with responders; NK 
immunophenotype characterized by a higher proportion of NK cell expressing the natural 
cytotoxicity receptor NKp30 compared to responders). Even if treated decompensated patients 
achieving SVR experience less adverse outcome, compared to non-treated and non SVR patients, in 
some cases the “virological cure” may not prevent disease progression or liver-related mortality 
Ac
ce
pte
d M
an
us
cri
pt
 
especially in case of more advanced liver disease. This is usually referred as “the point of no return” 
where anti-HCV treatment becomes futile. For this reason, DAAs are not required by patients with 
a limited life expectancy due to liver disease that cannot be remediated by antiviral treatment, LT or 
another directed therapy (31). However, the definition of this condition in patients not candidates 
for LT is challenging in the DAA era. In a post hoc analysis, DAAs are associated with significant 
decrease in mortality risk in patients with decompensated HCV cirrhosis, up to 60% by the end of 
the first year. About 4 months after therapy, the risk of death in decompensated patients receiving 
DAAs became statistically significantly lower than in a control population of untreated patients 
(32). Moreover, survival of HCV patients with hepatic decompensation may be predicted accurately 
using a short (90 days) term model based on MELD, sodium, albumin and hepatic encephalopathy 
(32) or by a recent BE3A score composed of body mass index (BMI), encephalopathy, ascites, ALT 
and albumin, able to predict clinical improvement to CPT A stage. The BE3A score can be 
calculated by the sum of its five components each has 1 point when the criterion is met: BMI <25, 
absence of encephalopathy, absence of ascites, ALT more than 1.5x upper limits of normal 
(ULN=60 IU/L) and albumin >3.5 g/dL. There were no significant differences in BE3A scores of 1-
5 in predicting LT or death. However, a BE3A score of 0 was associated with a 25% probability of 
death or a need for LT by week 36, with a sensitivity of 63% and a specificity of 75%. A BE3A 
score >1 was associated with 86-100% specificity of not having LT or death by week 36 (33). This 
score seems to have essentially a positive predictive value on survival in patients with 
decompensated liver disease, but it does not allow to accurately predicting liver related mortality. 
Thus the evaluation of the risk of death at three months in patients with decompensated cirrhosis 
should be based on a dynamic evaluation of clinical data in the single patient, including MELD, 
albumin, BMI, ALT levels, sodium, hepatic encephalopathy and ascites and reserved to centers with 
experience in the management of patients with end stage liver disease. The initial consideration 
when facing to decompensated cirrhotic patients is whether they are eligible or not for LT. In this 
latter case HCV eradication is the only potentially curative option, and therefore it should be 
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considered in all the patients. Conversely, in a LT-eligible decompensated patient the antiviral 
treatment has the goal to eradicate HCV in order to improve liver function, reduce portal 
hypertension-related complications and prevent post-LT HCV recurrence. In patients with 
decompensated liver disease the decision to start DAAs treatment should always be balanced 
between the potential benefits (high SVR rates in CTP B, reduced liver disease progression, 
increase in eligibility for HCC treatment, no increase in HCC activity after SVR, improvement 
quality of life [QOL] and reduced mortality on the waiting list, reduced post-LT HCV recurrence), 
and the potential harms (potentially greater risk of drug toxicity, lower SVR rates compared to post-
LT antiviral treatment, reduced priority for LT (purgatory effect), possibility to receive HCV-
positive graft).  
Since SVR rates are reduced in CPT B or C patients, the risk of the emergence of RASs must be 
taken into account in patients eligible for LT aiming to avoid an unwanted more difficult to treat 
post-LT recipient. The decision to treat a waitlisted patient with HCC should be individualized. 
Potential benefits and harms of antiviral therapy should be considered in the patient-provider shared 
decision in this setting, treatment to prevent recurrence should bear a lower priority, as highly 
effective therapies are available post-LT (34). The main issue to take into account when managing a 
waitlisted patients should be: anticipated time to LT, access to living donor LT, rate of availability 
of anti-HCV positive  donors and waiting list mortality rates. At present, CTP B and C patients with 
concomitant renal  impairment (CKD 4/5) represent a small but highly challenging patient 
populations. Reports on the HCV treatment in these cases are very limited and there are no 
published controlled clinical trials. All of the available DAAs combinations (GZR/ELB, GLE/PIB) 
for patients with CKD 4/5 contain PIs and are therefore contraindicated in patients with 
decompensated cirrhosis. On the other hand, despite the growing reports on safety and tolerability 
of SOF in patients with HCV and CKD 4/5, the SOF label limits its use in such patients (35,36). 
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Moreover, evidence does not support anti HCV treatment for HCV infected persons with limited 
life expectancy (<12 months) owing to non-liver related comorbidities. 
4.1 Statements 
• The benefits of DAAs are unlikely to be realized in: 
- CPT B or C patients not candidates for LT with a MELD>25 and without any of the 
following: BMI >25, normal albumin, absence of ascites or of hepatic encephalopathy, 
elevated ALT or normal sodium 
- Patients with limited life expectancy (<12 months) owing to non-liver related comorbidities 
• Patients with decompensated cirrhosis DAA regimens should include the combination of 
SOF plus VEL. Efficacy issues force to consider up to 24 weeks off-label treatment and RBV 
if tolerable 
4.2 LT–eligible patients 
4.2.1 Decompensated cirrhosis without HCC 
• CTP B and/or MELD <20 on the LT-waiting list without refractory portal hypertension-
related complications or other exceptions requiring urgent LT, should be treated with DAAs  
• Child C and or MELD >25 or patients with an expected LT-waiting list <3 months can be 
transplanted and treated with DAAs afterwards, in order to simplify treatment and improve 
its efficacy 
• Intermediate MELD (21-25) and/or low MELD scores with refractory portal hypertension-
related complications should be evaluated by an expert multidisciplinary team on a case-by-
case basis with  the perspective of delisting 
4.2.2 Decompensated cirrhosis with HCC 
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• Decompensated cirrhosis with HCC, with an expected LT-waiting list >3-6 months should 
be treated with DAAs whereas those with an expected LT-waiting list <3-6 months should 
not be treated with DAAs 
4.3 Decompensated cirrhosis with renal failure 
4.3.1 Non-LT eligible patients 
• These patients should be managed at a tertiary reference center and the decision whether to 
treat must be based on a case-by-case basis 
• A SOF-based PIs-free combination is at present the only off-label option (dose adjustments 
and close monitoring are recommended) 
• DAAs are not recommended in patients with hepatorenal syndrome 
4.3.2 LT-eligible patients 
• In candidates to combined liver/kidney transplant, DAAs should be deferred to post-LT 
 
5. HBV/HCV co-infection and DAAs 
Hepatitis B virus (HBV) and HCV are the most common etiologic factors of chronic liver disease 
and a major cause of anticipated liver-related mortality worldwide (1,37). Overall, the estimated 
prevalence of HBV among anti-HCV positive subjects ranges from 2% to 10% (37). Patients with 
HBV and HCV co-infection are at a higher risk of developing liver cirrhosis and HCC and may 
need either or both anti-HBV and anti-HCV treatments, depending on their viral status, by using 
therapeutic regimens for HBV or HCV mono-infection. Preliminary experiments suggested that 
HCV core protein could suppress HBV replication, however more "physiological" in vitro models 
proved that HBV and HCV can replicate in the same cell without evidence for direct interference 
(38). Furthermore, a longitudinal study in a cohort of 133 HBV/HCV co-infected patients showed a 
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complex spectrum of virological profiles with major fluctuations of HBV DNA or HCV RNA in 
one third of the cases (39). Thus, HBV replication also in the setting of HBV/HCV co-infection 
may have, in the HBeAg-negative phase, spontaneous fluctuations with temporary undetectable 
HBV DNA and subsequent reactivation. To accurately define the phase of the infection in carriers 
with low viremia, an adequate monitoring should be undertaken (37). Accordingly, some of the 
HBV reactivations reported in HCV co-infected patients treated with DAAs could be spontaneous 
fluctuations of HBV replication. Interestingly a recent meta-analysis reported a pooled proportion 
of HBV reactivation of 24% (95%CI: 19-30) in DAAs treated patients, similar to the spontaneous 
virological fluctuation observed in untreated HBV/HCV co-infected carriers (40). Nevertheless, the 
tight association of HBV reactivation with DAAs treatment, even if rarely (1.4%, 95%CI 0.8-2.4) 
also in HBsAg negative/anti-HBc positive patients, suggests that a modulation of the innate 
immune response following HCV clearance could favor a boost of HBV replication (41,42). In most 
of the cases the increase of HBV DNA serum levels is modest without ALT elevation, but cases of 
severe ALT flares eventually associated with liver decompensation had been reported (41,42). 
According to these data, the EASL HBV and HCV clinical practice guidelines (1,37) advise that 
HBsAg-positive patients undergoing DAAs should be considered for concomitant nucleot(s)ide 
analogs (NUCs) treatment or prophylaxis. However, it must be noted that most patients with 
HCV/HBV co-infection with advanced liver disease should be already on treatment with NUCs. 
HBV reactivations without hepatitis flares had been also reported in patients with occult HBV 
infection treated with DAAs (41,42). Accordingly, only a careful monitoring without an anti-HBV 
prophylaxis is recommended (1,37).  
5.1 Statements 
• All patients should be tested for HBsAg, anti-HBc IgG and anti-HBs before DAAs 
• Simultaneous administration of NUCs is recommended in patients fulfilling the standard 
criteria for HBV treatment  
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• HBsAg-positive patients undergoing DAAs, but without the standard criteria for HBV 
treatment should be considered, on single patient basis, according to the severity of liver 
disease, for concomitant NUCs prophylaxis until week 12 post DAA and further monitored 
closely  
• HBsAg-negative/anti-HBc IgG positive±anti-HBs positive patients undergoing DAAs should 
be tested  for HBV reactivation (HBsAg and/or HBV DNA) in case of ALT elevation  
 
6. HIV/HCV co-infection 
HIV/HCV co-infected patients with controlled HIV viremia remain at higher risk to have liver 
fibrosis progression than HIV mono-infected patients, for this reason is mandatory the treatment of 
HCV infection. The goal of HCV treatment is to achieve SVR, which is considered to be curative 
(1,31). Second wave of DAAs have closed the gap in treatment responses previously seen between 
mono- and co-infected patients. With the current regimens proving equally efficacy for both HCV 
mono-infected and HIV/HCV co-infected patients, the recommended regimens for co-infected 
patients are the same as for HCV mono-infected patients, with the additional consideration of 
potential DDIs with anti-HIV therapies. Shortening therapy (8 weeks treatment without RBV) may 
be feasible and cost-saving only in treatment-naïve patients with F0-2 and baseline HCV RNA <6 
million IU/ml (43). Active drug, alcohol abuse, neuropsychiatric disease and unstable housing 
among HIV/HCV co-infected persons continue to be ongoing barriers to access to care; however, 
several studies have presented convincing evidence that these issues are not contraindications to 
treatment and that patients with these disadvantages do not necessarily have reduced responses to 
therapy (44).  
6.1 Statements 
• Every person with HIV must be screened for HCV and viceversa 
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• Patients with HIV/HCV co-infection should be treated with DAAs regardless of liver disease 
stage and other concomitant comorbidities (drug abuse, alcoholism, psychiatric disorders)  
• Due to DDI between HIV and HCV PIs, a careful checking is needed before to start DDAs  
• Patients with HIV at high risk of HCV re-infection should be tested every 6 months for 
HCV-RNA after achieving SVR 
 
7. Management of DAA-failures 
Despite the excellent efficacy of DAAs, virological failures can occur and are often associated with 
development of resistance, with differences according to the type of regimen and HCV genotype 
(1,45-47). The natural presence of RASs, as well as their rapid emergence during incomplete drug 
pressure, is intrinsic characteristic of HCV that greatly affect treatment outcome and the chances to 
achieve a virological cure (48-50). Up today, a high number of RASs in NS3, NS5A, and NS5B 
have been associated in vivo and/or in vitro with reduced susceptibility to DAAs (51). Guidelines 
and experts on HCV treatment agree that understanding more about resistance may help the 
clinicians to learn why some patients failed, and may allow the optimization of both first and 
second-line treatment (1,2,31,52,53). The presence of drug-resistance at failure could represent an 
important issue for re-treatment options, especially when RASs are present in NS5A and/or in 
multiple DAA-targets. In DAA-failing patients, RASs prevalence and complexity are remarkably 
high, and in some cases of real life higher than previously reported (46-48). In particular, NS5A 
RASs at failure are very common (>90%), also with the new inhibitors VEL and PIB (54,55), and 
are very fit and tend to persist longer compared to NS3 and NS5B RASs (56). Furthermore, the 
presence of specific NS5A RASs before a first- and, even more, a second-line NS5A-including 
regimen can significantly affect the achievement of a SVR in HCV-1a and 3 cirrhotic patients (48-
50,54-58). 
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One proposed and frequently used approach for re-treatment after a virologic failure is to switch the 
DAA-class in combination with SOF, thanks to its high genetic barrier to resistance. This re-
treatment strategy had particularly sense when first-line regimen included a NS3 inhibitor. More 
complex is the situation today, when the majority of patients are using a NS5A inhibitor in first line, 
and in case of failure, the re-treatment could represent a big challenge. In this scenario, HCV 
resistance test could represent a helpful tool to characterize the presence of clinical relevant RASs 
for each specific DAA. In the new EASL guidelines, HCV resistance testing prior to re-treatment in 
patients who failed any DAA-containing regimens is considered useful to guide re-treatment in the 
context of a multidisciplinary team including experienced clinicians and virologists (1). Indeed, the 
resistance testing for all three genes (NS3, NS5A and NS5B) at virological failure after a DAAs 
was proposed in order to better guide re-treatment decisions (2,53). In addition, direct HCV 
sequencing in this setting also allows re-evaluating the infecting genotype and subtype.  
In cases of absence of RASs the choice of the new re-treatment can be facilitated among different 
options of regimens. Differently, in cases of high-grade multi-resistance (complex patterns to NS5A 
class and/or several classes), the combination of 3 or 4 drugs with different mechanisms of action, 
which affect all 3 genes, increasing the duration of the treatment and adding RBV, can improve the 
chances of cure (1,31,56-58). Indeed, as recommended by new AASLD 2017 and EASL 2018 
guidelines, the most reasonable approach is to re-treat patients with the new combination of 
SOF/VEL/VOX for 12 weeks (1,31). In case of presence of complex resistance and predictors of 
lower response (advanced liver disease, multiple courses of DAAs treatment, high viremia) it would 
be reasonable to evaluate the potential use of GLE/PIB in association with SOF for 12 weeks, and 
in case of very difficult-to-cure patients it has been recommended to evaluate both treatment options 
with RBV and/or with the extension of treatment to 16-24 weeks (1).  
7.1 Statements 
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• In DAA-exposed patients verify all possible causes of virologic failure: incorrect genotype, 
poor adherence and consider the possibility of re-infection. HCV resistance should be 
performed at the time of failure in certified laboratories, on all three genes to account for 
multiple RASs 
• Re-treatment options should be agreed between clinicians and virologists on RASs profile, 
viral load and patient characteristics   
• Off-label solutions (extension of duration, RBV use) can be considered for patients with 
complex resistance profiles  
8. The burden of HCV infection in Italy: how to bring out the hidden? 
Recently, Morisco et al. (59) assessed the prevalence and risk factors for HCV infection in the adult 
general population of Naples, selected from three general practitioner patient registers. The anti-
HCV prevalence was 3%, and 22.5% of anti-HCV positive subjects were previously unaware of 
their status. Similar data emerged from the study of Andriulli et al. (60) who assessed the 
prevalence and risk factors among Italian residents in 5 metropolitan areas. In this study 2.3 % of 
subjects tested anti-HCV positive and nearly 80% of anti-HCV positive subjects were aware of their 
status. In individuals attending the surgeries of 14 general practitioners working in Messina, 
Cacciola et al. (61) documented HCV infection in 69/1189 (5.8%) individuals with increased liver 
enzyme levels. Interestingly, 21/69 (30%) of anti-HCV individuals were anware of their infection. 
In our Country major barriers to the potential large use of DAAs have been low rates of HCV 
screening and diagnosis therefore effective screening programs are urgently needed to provide 
undiagnosed HCV-infected individuals with therapy and to spread information about preventive 
measures that should be taken to decrease future morbidity and mortality. In regions where the 
majority of patients belong to a well-defined age group, birth cohort testing has proven efficacious 
whereas systematic one-time testing has been recommended in countries with high endemicity 
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and/or with the goal of complete eradication. For this reason the optimal regional or national 
screening approaches should be determined and the screening strategies for HCV infection should 
be defined according to the local epidemiology of HCV infection. Screening strategies for HCV 
infection may include screening of populations at risk of infection, birth cohort testing, and general 
population testing in areas of intermediate to high seroprevalence (≥2%–5%) (1). Universal 
screening will yield low results and would not be cost-effective in low-prevalence countries where 
instead the risk-besed screening are more effective. In The US the Centers for Disease Control and 
Prevention (CDC) and the Preventive Services Task Force recommend screening for HCV for two 
groups of individuals (62,63): all individuals born in the years 1945-1965, based on the finding that 
approximately 75% of persons with a positive screening test and chronic HCV infection were born 
during the years 1945-1965 and in individuals with at least one of the following risk factors: have 
ever injected illegal drugs; received clotting factor concentrates produced before 1987; received 
blood or organs before July 1992; have been notified that they received blood from a donor who 
later tested positive for HCV infection; have ever been on chronic hemodialysis; have a persistently 
abnormal alanine aminotransferase level; were born to an HCV-positive mother; have HIV 
infection; have had a needle-stick injury or mucosal exposure to HCV-positive blood (healthcare, 
emergency medical, and public safety workers). 
Screening for HCV infection is performed by measuring antibody to HCV (anti-HCV) in a person's 
serum. A positive test (detection of the antibody) is not a diagnosis of the disease; it only indicates 
that a person was previously exposed to the virus. The currently available screening test has a 
sensitivity of at least 97% and a specificity of 100%. In addition to enzyme immunoassay (EIA) in 
serum or plasma, rapid diagnostic tests (RDTs) can be used to screen for anti-HCV antibodies. 
RDTs use various matrices, including serum and plasma, but also fingerstick capillary whole blood 
or oral (crevicular) fluid, facilitating screening without the need for venipuncture, tube 
centrifugation, freezing and skilled labour. RDTs are simple to perform at room temperature 
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without specific instrumentation or extensive training (1,64-66). Also dried blood spots can be used 
to collect whole blood specimens for EIA detection of anti-HCV antibodies in a central laboratory 
(67-69). If anti-HCV antibodies are detected, the presence of HCV RNA should be determined to 
identify patients with ongoing infection. Currently, most laboratories use a two-step approach that 
includes phlebotomy and an antibody test and phlebotomy and subsequently a test for HCV RNA. 
As a result, a substantial fraction of patients with anti-HCV antibodies never receive confirmatory 
HCV RNA testing (1). Therefore, reflex testing for HCV RNA should be applied whe never 
possible when anti-HCV antibodies are detected. The availability of point-of-care tests for HCV 
infection has the potential to simplify testing algorithms, increase diagnoses, and facilitate linkage 
to treatment. Moreover, several commercial assays detect HCV RNA (active HCV infection) in 60-
90 minute. All the further technological advances will enable access to low-cost, rapid, and accurate 
assays for HCV RNA detection, improving the number of people diagnosed with HCV infection 
and contributing to global elimination efforts (70-74). Most importantly such assays have the 
potential to simplify testing algorithms, increase diagnosis rates, and facilitate linkage to treatment, 
in low- and middle-income areas and in difficult-to reach populations, such as people who inject 
drugs (PWID). Depending upon relative costs, a direct test for HCV RNA and near-patient testing 
could be considered to replace screening based on anti-HCV antibody testing by the direct 
identification of viremic patients. In addition to identifying all the PWID infected patients, the other 
fundamental task is targeted counseling and risk assessment for men having sex with men (MSM) 
and inmates to strengthen education programs and to control the spread of the infection. MSM are 
the third most involved group in HCV transmission, after inmates and PWID, with prevalence up to 
4.7% (75). In recent years, there has been a rapid spread of HCV among MSM, particularly if HIV 
co-infected (76) and sexual behavior patterns likely drive HCV infection among MSM (77). Unlike 
other hard to reach populations such as PWID, the fact that HCV infection is more prevalent in 
HIV-positive MSM represents an advantage, given their link to care, the close monitoring and 
frequency of test. In this scenario, emerge the importance and the feasibility of HCV treatment 
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using DAAs (78). An interesting study on HCV transmission model conducted in UK, suggested 
that with a scale-up of DAAs use to 80% regardless of liver disease stage within 1 year from HCV 
diagnosis, and 20% every year after, could reduce the prevalence of chronic HCV infection up to 
71% in 2025, compared to the state of 2015. An additional value would be given by behavioral 
interventions, with a further decline of about 2.5% in the same decade (79).  
PWID are “hard-to-reach populations” whereas inmates are difficult to follow over time due to poor 
adherence and the fact that the latter are often moved from one prison to another not to mention that 
the services are not well designed to care for person with HCV in prison. Both these patient’s 
categories represent one of most important HCV reservoirs, with a seroprevalence up to 86% and 
84.3%, respectively. These findings suggest the high importance of such special sub-groups for 
HCV circulation among general population. DAAs could represent an important chance for 
reducing HCV circulation, and for the treatment of patients who are rarely reached by health-care 
services.  
In a HCV microsimulation model projecting the long-term benefits and costs of different HCV 
screening and treatment scenarios in US prisons, universal opt-out screening in prisons was highly 
cost-effective, reducing HCV transmission and associated disease in the outside community (80). 
Furthermore, a modeling study on HCV transmission among PWID in Scottish prisons, estimated 
that scaling up HCV treatment to include 80% of chronically infected PWID that enter the prison 
system with sentences of sufficient length (more than 12 weeks based on the assumption of 8-week 
DAA therapy) with an opioid substitution therapy (OST) coverage more than 50%, could reduce the 
incidence and prevalence of chronic HCV among PWID in Scotland by 55.8% (95%CI 49.3–
61.4%) and 55.9% (95%CI 51.1–61.3%), respectively (81). In essence, prison settings and 
methadone clinics could have a positive impact to screen and treat special subpopulation, normally 
with poor health-care provision and use. PWID with CHC attending OST community health clinics 
can achieve adherence and responses to anti-HCV treatment similar to other populations, despite 
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injecting drugs at baseline (82,83). PWID should be counselled on the importance of adherence in 
attaining an SVR. A history of IDU and recent drug use at treatment initiation are not associated 
with reduced SVR and decisions to treat should be made on a case-by-case basis. PWID with 
ongoing social issues, history of psychiatric disease and those with more frequent drug use during 
therapy are at risk of lower adherence and SVR and need to be monitored closely during therapy 
(84). In PWID we need a combination of strategie sto find those who are infected, get them treated 
and prevent transmission. However to get out of the HCV epidemic, we need to stop the 
transmission preventing the primary infection and then prevention of secondary infection, and harm 
reduction is a key element. Needle syringe program and OST are the primary intervention to reduce 
HCV transmission among people who inject drugs (85) 
In such patients the use of OST, NSP and screening campaigns, associated with the use of DAAs, is 
cost-effective and represents an exclusive opportunity to reach underserved populations and to 
reduce HCV infection to minimal levels (86). 
With regards the general population, a web-based model of best medical practice hab beeen showed 
to improve the management and the treatment of HCV patients with chronic hepatitis and cirrhosis. 
(87). 
8.1 Statement 
• The universalization of antiviral therapy for HCV infection must be pursued. The linkage to 
care must be optimized and standardized in order to ensure uniformity throughout the 
Country 
• Italian general practitioners should be sensitized on the benefits for patient and community 
to treat the largestnumber of infected patientsand therefore they should be involved in 
disease-specific testing and case finding  
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• Sensitization, information and prevention are essential to allow treatment of all patients 
with HCV infection and to reduce or abolish the transmission of HCV infection in risk 
groups  
• Needle syringe program and OST are the primary intervention to reduce HCV transmission 
among people who inject drugs 
• Inmates, PWID and MSM should be test and treat without delay  
• In undocumented migrants coming from low endemic countries universal screening is not 
recommendedbut direct access to healthcare services and DAAs treatment with 
transcultural formed staff and transcultural mediators is recommended 
• The web-based regional network models for the management of HCV infection must be 
incentivized as they have proved to be effective in guaranteeing fairness and transparency of 
treatment but they can also be used to disseminate information to general practitioners to 
bring out the submerged  
 
9. Conclusion 
Treatment of CHC has considerably improved in the last few years thanks to the introduction of 
DAAs able to achieve SVR in more than 95% of patients. Successful anti-HCV treatment can 
reduce HCV transmission, halt liver disease progression and solve the HCV-related extra-hepatic 
manifestations, eventually reducing both liver-related and overall mortality. In Italy, since march 
2017 SOF/VEL and GZR/EBR and from October 2017 GLE/PIB are reimbursable for all the HCV 
infected patients, whereas the combination of SOF/VEL/VOX is reimbursable since April 2018 
only for those who have failed a previous DAA-based regimen. The use of DAAs in clinical 
practice has confirmed the effectiveness and safety of these regimens reported in registration trials 
thus favoring an extended use in all infected patients. 
10. Expert Opinion 
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A number of different studies have shown a clear reduction in the quality of life of CHC-related 
liver-disease patients. Thse subjects are aware that CHC can progress to cirrhosis or liver cancer 
and may experience social isolation, anxiety, and psychological distress, which negatively affected 
their social lives and family relationship. Longitudinal studies have proved that, following 
diagnosis, the stigma of liver disease becomes more apparent over time. CHC patients consider their 
disease shameful and filthy due to the social stigma that hepatitis C infection is acquired through 
drug abuse, including narcotics, and risky sexual behaviors. Studies also suggested that these 
patients are concerned that they may infect the people around them owing to the lack of knowledge 
on the disease process of hepatitis C. Moreover, they can have bad relationship with their family or 
be isolated from society because of physical tiredness or feelings of powerlessness. As such, CHC 
is found to widely affect the patients’ personal and family lives and even the society in general, 
indicating that efforts need to be made to improve their health-related quality of life. 
However, in the last years the approach to HCV infection has been dramatically changed following 
the introduction of the new DAAs. Early improvement in the quality of life of patients who become 
HCV RNA negative suggests that the virus itself plays a biological role (88,89). 
Achievement of SVR with antiviral treatment has been associated with the reduction of HCV 
transmission, improvement of hepatic inflammation and fibrosis, liver function and survival and 
their associated costs (90).  
DAAs have shown high efficacy and safety also in those patients previously defined as “difficult 
patients”, including those with more advanced liver disease. In such patients the risk of 
complications and mortality have been reduced after SVR although in some cases the “virological 
cure” may not prevent disease progression or liver-related mortality as well as in cirrhotic patients 
obtaining SVR reduces but does not completely eliminate the risk of HCC. However, after an initial 
phase characterized by the prioritization of the patients with more severe liver disease, necessary to 
face the costs of the drugs in relation to the high number of treatments required, we are now in a 
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phase of universalization of the access to therapy to all infected patients for which the benefit of 
treatment will be significantly greater. In the near future the number of patients with advances liver 
disease should gradually disappear and only patients with mild liver disease will remain to be 
treated.   
It is certain that the results achieved so far in CHC patients with the currently approved drugs are 
excellent and no further regimens are in clinical development. The extension of HCV cure to all 
infected subjects will further amplify the health benefits while maintaining a favorable cost-benefit 
ratio. Treating patients with early liver disease will reduce the mortality related to the progression of 
liver injury and extrahepatic complications, curb the transmission of infection from some persistent 
reservoirs and improve the patients' quality of life. The reduction in the costs of drugs that have 
been witnessed in the last year will contribute to the benefits of this therapeutic strategy. However, 
the advantages of this process of universalization can only be maximized if supported by an 
effective policy of awareness, information and prevention and if the ability to access treatment will 
be the same for all patients. The main objective is to establish the tools for a precise 
epidemiological evaluation, correct information of the categories at risk of contracting and 
transmitting the infection, enhance screening program both in the general population and in the 
higher risk patients and an adequate training of healthcare workers.  
In the absence of an effective vaccine, treatment of all infected patients is the only strategy that can 
lead to the elimination of the virus as desired by the World Health Organization (WHO) by 2030. 
The WHO strategy has a vision of eliminating viral hepatitis as a public health problem and this is 
encapsulated in the global targets of reducing new viral hepatitis infections by 90% and reducing 
deaths due to viral hepatitis by 65% increasing then testing awarness by 90% and the number of 
treated by 80% (91).  
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Table Legend 
Table 1: Baseline clinical, demographic and virological characteristics of 10,711 patients with 
available SVR12 data after DAAs treatment. 
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Table- Baseline clinical, demographic and virological characteristics of 10,711 patients with 
available SVR12 data after DAAs treatment.  
Characteristics  
Age, yrs* 62 (18-88) 
Age ≥65 years  4644 (43%) 
Male, n (%) 6459 (60%) 
Genotype, n (%) 
1a 
1b 
2 
3 
4 
Others or not available 
 
1465 (14%) 
5788 (54%) 
1279 (12%) 
1217 (11%) 
863 (8%) 
99 (1%) 
Compensated cirrhosis, n (%) 7121 (66%) 
Decompensated cirrhosis, n (%) 714 (7%) 
BMI*, kg/m2 25 (14-48) 
ALT, IU/L* 74 (6-1178) 
INR* 1.06 (0.8-3.6) 
Platelets x 103/mm3* 135 (12-1151) 
Albumin, g/dL* 4.0 (2.0-5.6) 
Bilirubin, mg/dL* 0.84 (0.2-31) 
Creatinine, mg/dL* 0.8 (0.2-9.7) 
*median (range) 
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